AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 181 min read$DVA

DaVita (NYSE: DVA) reports new insider stock trade

DaVita (DVA) reported an insider stock transaction. A director acquired 278 shares of common stock and disposed of 14,021 shares indirectly. The transaction occurred on August 15, 2026, according to the SEC filing.

Original reporting
stocktitan.net
Published Aug 18, 2026, 10:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$DVA
Neutral
high confidence
Mentioned
$DVA
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$DVANeutralLow
01

Why it matters

The director's purchase is minimal and does not suggest a material shift in ownership or strategy.

02

Market read

Routine insider filing with negligible trading relevance.

03

What to watch

The filing does not disclose the purchase price; market may interpret the zero price entry as a reporting artifact.

Relevance 4/10Novelty 3/10Timing: today

Background

Form 4 disclosures are primary sources for insider transactions and are routinely reported by market data services.

Company-level read

Ticker impact

$DVANeutralHigh confidence
Context

Director filed a Form 4 on 08/18/2026 showing acquisition of 278 shares of DaVita (DVA) on 08/15/2026.

Expected impact

No material price impact expected.

Evidence & confidence

The transaction size is trivial relative to DaVita's float and the insider already holds a large position.

Market effects

Sector

None; DaVita operates in healthcare services and the filing does not affect sector trends.

Regional

None; the trade is specific to DaVita and does not influence broader regional markets.

Global

Low; isolated insider transaction with no macro implications.

Counterpoint

What could challenge this read

If the director is signaling confidence, a small buy could precede a larger strategic move.

Key entities

  • Company
    DaVita Inc.

    U.S.-listed provider of kidney dialysis services.

  • Entity
    Marc J. Desoer and Barbara J. Desoer 1998 Trust

    Indirect ownership vehicle for the director's shares.

Read at source← All news

Related articles

AUG 27
$DVAMedAI 8/10

Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)

Berkshire Hathaway's largest proportional holding is in DaVita (DVA), a kidney dialysis center operator, with a 45% stake. Berkshire has reduced its position from 36.1 million to 28.7 million shares since early 2025. DaVita's stock is up 56% year-to-date, with Q1 revenue of $3.4 billion and adjusted profit of $198 million. The company raised its EPS guidance to $14.10-$15.20.

fool.com2 min
AUG 8
$DVAMed

DaVita Shares Rise After TD Cowen Upgrades Stock to Buy

DaVita HealthCare Partners (NYSE:DVA) rose about 2.1% premarket after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and long-term growth. The upgrade followed DaVita’s Q2 2026 results: adjusted EPS $4.02 vs $3.92 expected, revenue about $3.55B vs estimates, while guidance stayed unchanged.

yahoo.com5 min
AUG 7
$DVAMed

Why is DaVita stock up 2% today?

DaVita HealthCare Partners (DVA) rose about 2.1% in pre-open trading after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and MOTheR trial results. The upgrade followed DaVita’s Q2 2026 beat, with adjusted EPS of $4.02 vs $3.92 and revenue of about $3.55B vs forecasts, despite flat guidance.

investing.com3 min
AUG 6
$DVAMed

DaVita Inc. Q2 2026 Earnings Call Summary

DaVita reported Q2 2026 updates on dialysis operations, citing improved patient mortality and a Medicare bundle shift that reduced reliance on OTC phosphate binders by over 50%. Revenue per treatment fell sequentially. DaVita reconfirmed 2026 adjusted operating income guidance of $2.2B and expects 2026 treatment growth at the top of 25-50 bps. FDA approval of NIPRO expanded HD dialyzers may improve supply.

yahoo.com7 min